Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate Patent Expiration
Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate is Used for managing HIV-1 infection in adults and pediatric patients aged 12 years and older. It was first introduced by Gilead Sciences Llc
Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate Patents
Given below is the list of patents protecting Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Atripla | US5519021 | Benzoxazinones as inhibitors of HIV reverse transcriptase |
May 21, 2013
(Expired) | Gilead Sciences |
| Atripla |
US5519021 (Pediatric) | Benzoxazinones as inhibitors of HIV reverse transcriptase |
Nov 21, 2013
(Expired) | Gilead Sciences |
| Atripla | US5663169 | Benzoxazinones as inhibitors of HIV reverse transcriptase |
Sep 02, 2014
(Expired) | Gilead Sciences |
| Atripla |
US5663169 (Pediatric) | Benzoxazinones as inhibitors of HIV reverse transcriptase |
Mar 02, 2015
(Expired) | Gilead Sciences |
| Atripla | US5811423 | Benzoxazinones as inhibitors of HIV reverse transcriptase |
Aug 07, 2012
(Expired) | Gilead Sciences |
| Atripla | US5814639 | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep 29, 2015
(Expired) | Gilead Sciences |
| Atripla |
US5814639 (Pediatric) | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Mar 29, 2016
(Expired) | Gilead Sciences |
| Atripla | US5914331 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul 02, 2017
(Expired) | Gilead Sciences |
| Atripla |
US5914331 (Pediatric) | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jan 02, 2018
(Expired) | Gilead Sciences |
| Atripla | US5922695 | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul 25, 2017
(Expired) | Gilead Sciences |
| Atripla |
US5922695 (Pediatric) | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jan 25, 2018
(Expired) | Gilead Sciences |
| Atripla | US5935946 | Nucleotide analog composition and synthesis method |
Jul 25, 2017
(Expired) | Gilead Sciences |
| Atripla |
US5935946 (Pediatric) | Nucleotide analog composition and synthesis method |
Jan 25, 2018
(Expired) | Gilead Sciences |
| Atripla | US5977089 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul 25, 2017
(Expired) | Gilead Sciences |
| Atripla |
US5977089 (Pediatric) | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan 25, 2018
(Expired) | Gilead Sciences |
| Atripla | US6043230 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul 25, 2017
(Expired) | Gilead Sciences |
| Atripla |
US6043230 (Pediatric) | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan 25, 2018
(Expired) | Gilead Sciences |
| Atripla | US6639071 | Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
Feb 14, 2018
(Expired) | Gilead Sciences |
| Atripla |
US6639071 (Pediatric) | Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
Aug 14, 2018
(Expired) | Gilead Sciences |
| Atripla | US6642245 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov 04, 2020
(Expired) | Gilead Sciences |
| Atripla |
US6642245 (Pediatric) | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
May 04, 2021
(Expired) | Gilead Sciences |
| Atripla | US6703396 | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar 09, 2021
(Expired) | Gilead Sciences |
| Atripla |
US6703396 (Pediatric) | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Sep 09, 2021
(Expired) | Gilead Sciences |
| Atripla | US6939964 | Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
Jan 20, 2018
(Expired) | Gilead Sciences |
| Atripla |
US6939964 (Pediatric) | Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
Jul 20, 2018
(Expired) | Gilead Sciences |
| Atripla | US8592397 | Compositions and methods for combination antiviral therapy |
Jan 13, 2024
(Expired) | Gilead Sciences |
| Atripla | US8598185 | Unitary pharmaceutical dosage form | Apr 28, 2029 | Gilead Sciences |
| Atripla | US8716264 | Compositions and methods for combination antiviral therapy |
Jan 13, 2024
(Expired) | Gilead Sciences |
| Atripla |
US8716264 (Pediatric) | Compositions and methods for combination antiviral therapy |
Jul 03, 2024
(Expired) | Gilead Sciences |
| Atripla | US9018192 | Unitary pharmaceutical dosage form | Jun 13, 2026 | Gilead Sciences |
| Atripla | US9457036 | Compositions and methods for combination antiviral therapy |
Jan 13, 2024
(Expired) | Gilead Sciences |
| Atripla | US9545414 | Unitary pharmaceutical dosage form | Jun 13, 2026 | Gilead Sciences |
| Atripla | US9744181 | Compositions and methods for combination antiviral therapy |
Jan 13, 2024
(Expired) | Gilead Sciences |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate Generics
Several generic applications have been filed for Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate. The first generic version for Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate was by Aurobindo Pharma Ltd and was approved on Sep 4, 2018. And the latest generic version is by Strides Pharma Global Pte Ltd and was approved on Oct 3, 2023.
Given below is the list of companies who have filed for Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate generic.
1. CIPLA
Cipla Ltd has filed for 1 generic for Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate. This 600mg;200mg;300mg version comes by the name EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE. Given below are the details of the strengths of this generic introduced by Cipla.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 600MG; 200MG; 300MG | tablet | Prescription | ORAL | AB | Jun 3, 2019 |
2. TEVA PHARMS USA
Teva Pharmaceuticals Usa has filed for 1 generic for Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate. This 600mg;200mg;300mg version comes by the name EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 600MG; 200MG; 300MG | tablet | Prescription | ORAL | AB | Nov 9, 2018 |
3. STRIDES PHARMA
Strides Pharma Global Pte Ltd has filed for 1 generic for Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate. This 600mg;200mg;300mg version comes by the name EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE. Given below are the details of the strengths of this generic introduced by Strides Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 600MG; 200MG; 300MG | tablet | Discontinued | ORAL | N/A | Oct 3, 2023 |
4. HETERO LABS LTD V
Hetero Labs Ltd Unit V has filed for 1 generic for Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate. This 600mg;200mg;300mg version comes by the name EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd V.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 600MG; 200MG; 300MG | tablet | Prescription | ORAL | AB | Jan 24, 2022 |
5. LAURUS
Laurus Labs Ltd has filed for 1 generic for Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate. This 600mg;200mg;300mg version comes by the name EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE. Given below are the details of the strengths of this generic introduced by Laurus.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 600MG; 200MG; 300MG | tablet | Prescription | ORAL | AB | Dec 22, 2021 |
6. AUROBINDO PHARMA
Aurobindo Pharma Ltd has filed for 1 generic for Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate. This 600mg;200mg;300mg version comes by the name EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 600MG; 200MG; 300MG | tablet | Prescription | ORAL | AB | Sep 4, 2018 |
7. MACLEODS PHARMS LTD
Macleods Pharmaceuticals Ltd has filed for 1 generic for Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate. This 600mg;200mg;300mg version comes by the name EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE. Given below are the details of the strengths of this generic introduced by Macleods Pharms Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 600MG; 200MG; 300MG | tablet | Prescription | ORAL | AB | Sep 13, 2021 |